Researchers have identified a drug target that may alleviate joint degeneration associated with osteoarthritis.
Osteoarthritis is a debilitating condition that affects as many as 30 million people in the United States alone.
Pain relievers and lifestyle changes, such as exercise and reduced excess weight, have long been the therapies most commonly used to treat the joint stiffness and pain caused by the degenerative disease, but there is a pressing need for therapies that can prevent joint breakdown that occurs in osteoarthritis.
It is known that specialized proteins known as sodium channels found in cell membranes produce electrical impulses in “excitable” cells within muscles, the nervous system, and the heart.
In previous research, Stephen G. Waxman, professor of neurology, of neuroscience, and of pharmacology at Yale University School of Medicine identified the key role of one particular sodium channel, called Nav1.7, in the transmission of pain signals.
Now, the labs of Chuan-Ju Liu, professor of orthopedics at Yale School of Medicine, and Waxman have found that the same Nav1.7 channels are also present in non-excitable cells that produce collagen and help maintain the joints in the body.
Osteoarthritis, the most common form of arthritis, is a degenerative disease caused by the breakdown of cartilage that eases friction between the joints. It occurs most commonly in the hands, hips, and knees.
In the new study, the researchers deleted Nav1.7 genes from these collagen-producing cells and significantly reduced joint damage in two osteoarthritis models in mice.
They also demonstrated that drugs used to block Nav1.7—including carbamazepine, a sodium channel blocker currently used to treat epilepsy and trigeminal neuralgia—also provided substantial protection from joint damage in the mice.
“The function of sodium channels in non-excitable cells has been a mystery,” Waxman says. “This new study provides a window on how small numbers of sodium channels can powerfully regulate the behavior of non-excitable cells.”
“The findings open new avenues for disease-modifying treatments,” says Wenyu Fu, a research scientist in the Liu laboratory and first author of the study in Nature.
Source: Yale University
